Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, Wetzels JFM, Cheung M, Wheeler DC, Winkelmayer WC, Rovin BH; Conference Participants.

Kidney Int. 2019 Feb;95(2):268-280. doi: 10.1016/j.kint.2018.10.018.

PMID:
30665568
2.

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.

Thompson A, Carroll K, A Inker L, Floege J, Perkovic V, Boyer-Suavet S, W Major R, I Schimpf J, Barratt J, Cattran DC, S Gillespie B, Kausz A, W Mercer A, Reich HN, H Rovin B, West M, Nachman PH.

Clin J Am Soc Nephrol. 2019 Jan 11. pii: CJN.08600718. doi: 10.2215/CJN.08600718. [Epub ahead of print]

PMID:
30635299
3.

Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.

Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y, Cattran DC, Chishti AS, D'Agati VD, D'Alessandri-Silva CJ, Gbadegesin RA, Hogan JJ, Iragorri S, Jennette JC, Julian BA, Khalid M, Lafayette RA, Liapis H, Lugani F, Mansfield SA, Mason S, Nachman PH, Nast CC, Nester CM, Noone DG, Novak J, O'Shaughnessy MM, Reich HN, Rheault MN, Rizk DV, Saha MK, Sanghani NS, Sperati CJ, Sreedharan R, Srivastava T, Swiatecka-Urban A, Twombley K, Vasylyeva TL, Weaver DJ, Yin H, Zee J, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Flessner M, Guay-Woodford LM, Kiryluk K; CureGN Consortium.

Kidney Int Rep. 2018 Aug 3;3(6):1373-1384. doi: 10.1016/j.ekir.2018.07.021. eCollection 2018 Nov.

4.

Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy.

Reynolds ML, Nachman PH, Mooberry MJ, Crona DJ, Derebail VK.

J Nephrol. 2018 Nov 12. doi: 10.1007/s40620-018-0552-9. [Epub ahead of print]

PMID:
30421320
5.

CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.

Mariani LH, Bomback AS, Canetta PA, Flessner MF, Helmuth M, Hladunewich MA, Hogan JJ, Kiryluk K, Nachman PH, Nast CC, Rheault MN, Rizk DV, Trachtman H, Wenderfer SE, Bowers C, Hill-Callahan P, Marasa M, Poulton CJ, Revell A, Vento S, Barisoni L, Cattran D, D'Agati V, Jennette JC, Klein JB, Laurin LP, Twombley K, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson B, Smoyer WE, Guay-Woodford LM; CureGN Consortium.

Am J Kidney Dis. 2019 Feb;73(2):218-229. doi: 10.1053/j.ajkd.2018.07.020. Epub 2018 Nov 9.

PMID:
30420158
6.

Repeat kidney biopsy for lupus nephritis: an important step forward.

Nachman PH.

Kidney Int. 2018 Oct;94(4):659-661. doi: 10.1016/j.kint.2018.06.026.

PMID:
30243311
7.

Persistent Hematuria in ANCA Vasculitis: Ominous or Innocuous?

Mahoney SL, Nachman PH.

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):201-202. doi: 10.2215/CJN.14101217. Epub 2018 Jan 25. No abstract available.

8.

An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.

Troost JP, Trachtman H, Nachman PH, Kretzler M, Spino C, Komers R, Tuller S, Perumal K, Massengill SF, Kamil ES, Oh G, Selewski DT, Gipson P, Gipson DS.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):414-421. doi: 10.2215/CJN.04780517. Epub 2017 Nov 22.

PMID:
29167190
9.

ANCA Glomerulonephritis and Vasculitis.

Jennette JC, Nachman PH.

Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1680-1691. doi: 10.2215/CJN.02500317. Epub 2017 Aug 25. Review.

10.

Interstital lung disease in ANCA vasculitis.

Alba MA, Flores-Suárez LF, Henderson AG, Xiao H, Hu P, Nachman PH, Falk RJ, Charles Jennette J.

Autoimmun Rev. 2017 Jul;16(7):722-729. doi: 10.1016/j.autrev.2017.05.008. Epub 2017 May 4. Review.

11.

Pregnancy Outcomes in Patients with Glomerular Disease Attending a Single Academic Center in North Carolina.

O'Shaughnessy MM, Jobson MA, Sims K, Liberty AL, Nachman PH, Pendergraft WF.

Am J Nephrol. 2017;45(5):442-451. doi: 10.1159/000471894. Epub 2017 Apr 27.

PMID:
28445873
12.

Calcineurin Inhibitors in the Treatment of Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis of the Literature.

Laurin LP, Nachman PH, Foster BJ.

Can J Kidney Health Dis. 2017 Feb 22;4:2054358117692559. doi: 10.1177/2054358117692559. eCollection 2017. Review.

13.

The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy.

Brown LC, Jobson MA, Payan Schober F, Chang EH, Falk RJ, Nachman PH, Pendergraft WF.

Am J Nephrol. 2017;45(4):365-372. doi: 10.1159/000464475. Epub 2017 Mar 18.

14.

Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis.

Payan Schober F, Jobson MA, Poulton CJ, Singh HK, Nickeleit V, Falk RJ, Jennette JC, Nachman PH, Pendergraft Iii WF.

Am J Nephrol. 2017;45(3):248-256. doi: 10.1159/000455390. Epub 2017 Feb 4.

15.

Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS.

Laurin LP, Gasim AM, Derebail VK, McGregor JG, Kidd JM, Hogan SL, Poulton CJ, Detwiler RK, Jennette JC, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1752-1759. doi: 10.2215/CJN.13091215. Epub 2016 Jul 21.

16.

Patients with primary membranous nephropathy are at high risk of cardiovascular events.

Lee T, Derebail VK, Kshirsagar AV, Chung Y, Fine JP, Mahoney S, Poulton CJ, Lionaki S, Hogan SL, Falk RJ, Cattran DC, Hladunewich M, Reich HN, Nachman PH.

Kidney Int. 2016 May;89(5):1111-1118. doi: 10.1016/j.kint.2015.12.041. Epub 2016 Feb 26.

PMID:
26924046
17.

Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS.

Laurin LP, Gasim AM, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Foster BJ, Nachman PH.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):386-94. doi: 10.2215/CJN.07110615. Epub 2016 Feb 16.

18.

Complete Remission in the Nephrotic Syndrome Study Network.

Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):81-9. doi: 10.2215/CJN.02560315. Epub 2015 Dec 10.

19.

Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy.

Thompson A, Cattran DC, Blank M, Nachman PH.

J Am Soc Nephrol. 2015 Dec;26(12):2930-7. doi: 10.1681/ASN.2015010091. Epub 2015 Jun 15.

20.

Recent pathogenetic advances in ANCA-associated vasculitis.

Pendergraft WF 3rd, Nachman PH.

Presse Med. 2015 Jun;44(6 Pt 2):e223-9. doi: 10.1016/j.lpm.2015.04.007. Epub 2015 May 29. Review.

PMID:
26033562
21.

Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis.

Bunch DO, Mendoza CE, Aybar LT, Kotzen ES, Colby KR, Hu Y, Hogan SL, Poulton CJ, Schmitz JL, Falk RJ, Nachman PH, Pendergraft WF, McGregor JG.

Ann Rheum Dis. 2015 Sep;74(9):1784-6. doi: 10.1136/annrheumdis-2014-206756. Epub 2015 Apr 30. No abstract available.

22.

Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function.

McGregor JG, Negrete-Lopez R, Poulton CJ, Kidd JM, Katsanos SL, Goetz L, Hu Y, Nachman PH, Falk RJ, Hogan SL.

Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i171-81. doi: 10.1093/ndt/gfv045.

23.

Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.

McGregor JG, Hogan SL, Kotzen ES, Poulton CJ, Hu Y, Negrete-Lopez R, Kidd JM, Katsanos SL, Bunch DO, Nachman PH, Falk RJ.

Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i123-31. doi: 10.1093/ndt/gfv076.

24.

Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure.

Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, Lionaki S, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2014 May;9(5):905-13. doi: 10.2215/CJN.08290813. Epub 2014 Feb 27.

25.

Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy.

Lee T, Biddle AK, Lionaki S, Derebail VK, Barbour SJ, Tannous S, Hladunewich MA, Hu Y, Poulton CJ, Mahoney SL, Charles Jennette J, Hogan SL, Falk RJ, Cattran DC, Reich HN, Nachman PH.

Kidney Int. 2014 Jun;85(6):1412-20. doi: 10.1038/ki.2013.476. Epub 2013 Dec 11.

26.

Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease.

Laurin LP, Nachman PH, Desai PC, Ataga KI, Derebail VK.

Nephrol Dial Transplant. 2014 Jun;29(6):1211-8. doi: 10.1093/ndt/gft295. Epub 2013 Sep 30.

27.

Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis.

Roth AJ, Ooi JD, Hess JJ, van Timmeren MM, Berg EA, Poulton CE, McGregor J, Burkart M, Hogan SL, Hu Y, Winnik W, Nachman PH, Stegeman CA, Niles J, Heeringa P, Kitching AR, Holdsworth S, Jennette JC, Preston GA, Falk RJ.

J Clin Invest. 2013 Apr;123(4):1773-83. doi: 10.1172/JCI65292. Epub 2013 Mar 15.

28.

Pathways to renal biopsy and diagnosis among patients with ANCA small-vessel vasculitis.

Poulton CJ, Nachman PH, Hu Y, McGregor JG, Jennette JC, Falk RJ, Hogan SL.

Clin Exp Rheumatol. 2013 Jan-Feb;31(1 Suppl 75):S32-7. Epub 2013 Jan 23.

29.

Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach.

Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PX, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ, Lienczewski CC, Adler SG, Appel GB, Cattran DC, Choi MJ, Contreras G, Dell KM, Fervenza FC, Gibson KL, Greenbaum LA, Hernandez JD, Hewitt SM, Hingorani SR, Hladunewich M, Hogan MC, Hogan SL, Kaskel FJ, Lieske JC, Meyers KE, Nachman PH, Nast CC, Neu AM, Reich HN, Sedor JR, Sethna CB, Trachtman H, Tuttle KR, Zhdanova O, Zilleruelo GE, Kretzler M.

Kidney Int. 2013 Apr;83(4):749-56. doi: 10.1038/ki.2012.428. Epub 2013 Jan 16.

30.

Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2013 Mar;8(3):382-91. doi: 10.2215/CJN.03950412. Epub 2013 Jan 4.

31.

Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.

Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, Nachman PH, Jennette JC, Falk RJ.

Arthritis Rheum. 2012 Oct;64(10):3452-62. doi: 10.1002/art.34562.

32.

Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.

Irazabal MV, Eirin A, Lieske J, Beck LH, Sethi S, Borland TM, Dillon JJ, Nachman PH, Nasr SH, Cornell LD, Leung N, Cattran DC, Fervenza FC.

Nephrol Dial Transplant. 2013 Jan;28(1):137-46. doi: 10.1093/ndt/gfs379. Epub 2012 Sep 17.

33.

Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease.

McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2012 Feb;7(2):240-7. doi: 10.2215/CJN.05610611. Epub 2011 Dec 1.

34.

Venous thromboembolism in patients with membranous nephropathy.

Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN.

Clin J Am Soc Nephrol. 2012 Jan;7(1):43-51. doi: 10.2215/CJN.04250511. Epub 2011 Nov 10.

35.

Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis.

Barbour SJ, Greenwald A, Djurdjev O, Levin A, Hladunewich MA, Nachman PH, Hogan SL, Cattran DC, Reich HN.

Kidney Int. 2012 Jan;81(2):190-5. doi: 10.1038/ki.2011.312. Epub 2011 Sep 14.

36.

Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients.

Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, Rosamond WD, Kshirsagar AV.

Kidney Int. 2011 Nov;80(9):992-999. doi: 10.1038/ki.2011.247. Epub 2011 Aug 17.

37.

Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans.

Hicks PJ, Langefeld CD, Lu L, Bleyer AJ, Divers J, Nachman PH, Derebail VK, Bowden DW, Freedman BI.

Kidney Int. 2011 Dec;80(12):1339-43. doi: 10.1038/ki.2011.286. Epub 2011 Aug 17.

38.

Pathogenesis of lung vasculitis.

Nachman PH, Henderson AG.

Semin Respir Crit Care Med. 2011 Jun;32(3):245-53. doi: 10.1055/s-0031-1279822. Epub 2011 Jun 14. Review.

PMID:
21674411
39.

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC; Mayo Nephrology Collaborative Group.

Clin J Am Soc Nephrol. 2010 Dec;5(12):2188-98. doi: 10.2215/CJN.05080610. Epub 2010 Aug 12.

40.

High prevalence of sickle cell trait in African Americans with ESRD.

Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, Kshirsagar AV.

J Am Soc Nephrol. 2010 Mar;21(3):413-7. doi: 10.1681/ASN.2009070705. Epub 2010 Jan 7.

41.

The clinical course of ANCA small-vessel vasculitis on chronic dialysis.

Lionaki S, Hogan SL, Jennette CE, Hu Y, Hamra JB, Jennette JC, Falk RJ, Nachman PH.

Kidney Int. 2009 Sep;76(6):644-51. doi: 10.1038/ki.2009.218. Epub 2009 Jun 17.

42.

Vasculitis syndromes: which maintenance therapy for ANCA vasculitis?

Nachman PH.

Nat Rev Nephrol. 2009 May;5(5):254-6. doi: 10.1038/nrneph.2009.52.

PMID:
19384325
43.

Rituximab therapy for membranous nephropathy: a systematic review.

Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2009 Apr;4(4):734-44. doi: 10.2215/CJN.05231008. Epub 2009 Mar 11. Review.

44.

Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.

Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, Nachman PH.

Arthritis Rheum. 2008 Sep;58(9):2908-18. doi: 10.1002/art.23800.

45.

Maintenance of tolerance by regulation of anti-myeloperoxidase B cells.

Bunch DO, Silver JS, Majure MC, Sullivan P, Alcorta DA, Chin H, Hogan SL, Lindstrom YI, Clarke SH, Falk RJ, Nachman PH.

J Am Soc Nephrol. 2008 Sep;19(9):1763-73. doi: 10.1681/ASN.2007030382. Epub 2008 Jul 23.

46.

Vasculitis and anti-thyroid medication.

Lionaki S, Hogan SL, Falk RJ, Joy MS, Jennette CE, Nachman PH, Jennette JC.

Nephrol Dial Transplant. 2008 May;23(5):1766-8; author reply 1768. doi: 10.1093/ndt/gfm887. Epub 2007 Dec 21. No abstract available.

47.

Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study.

Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, Jennette JC, Nachman PH.

Nephrol Dial Transplant. 2007 Dec;22(12):3508-15. Epub 2007 Aug 8.

PMID:
17686815
48.

Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance loss.

Culton DA, Nicholas MW, Bunch DO, Zhen QL, Kepler TB, Dooley MA, Mohan C, Nachman PH, Clarke SH.

J Clin Immunol. 2007 Jan;27(1):53-68. Epub 2006 Dec 29.

PMID:
17195045
49.

Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using human-mouse MPO chimers.

Erdbrügger U, Hellmark T, Bunch DO, Alcorta DA, Jennette JC, Falk RJ, Nachman PH.

Kidney Int. 2006 May;69(10):1799-805.

50.

Various forms of life in antineutrophil cytoplasmic antibody-associated vasculitis.

Hogan SL, Falk RJ, Nachman PH, Jennette JC.

Ann Intern Med. 2006 Mar 7;144(5):377-8; author reply 378-9. No abstract available.

PMID:
16520483

Supplemental Content

Loading ...
Support Center